Open-label, Dose Escalation Study of Safety and Preliminary Efficacy of TN-401 in Adults with PKP2 Mutation-associated ARVC (RIDGE-1)

Tenaya Therapeutics

Status and phase

Enrolling

Phase 1

Conditions

Arrhythmogenic Right Ventricular Cardiomyopathy

Treatments

Genetic: TN-401

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT06228924

TN-401-0012

Details and patient eligibility

About

This first-in-human study is designed to evaluate the safety, and preliminary efficacy (PD) of TN-401 gene therapy in adult patients with symptomatic PKP2 mutation-associated ARVC.

Full description

The RIDGE-1™ open-label Safety, Tolerability, Dose-finding, PD and Cardiac Transgene Expression Study will enroll up to 15 patients in two planned dose cohorts. Patients in each cohort will receive a single intravenous (IV) dose of TN-401. Following Data Safety Monitoring Board (DSMB) review of each dose cohort, the next dose cohort will be initiated. DSMB review will also be needed to expand the dose cohorts. The dose for Cohorts 1/1a will be 3E13 (3 × 1013) vg/kg and the dose for Cohorts 2/2a will be 6E13 (6 × 1013) vg/kg.

Enrollment

15 estimated patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

PKP2 mutation (pathogenic or likely pathogenic)
Arrhythmogenic Right Ventricular Cardiomyopathy as defined by the 2010 revised Task Force Criteria
Left Ventricular Ejection Fraction ≥50%
Functioning Implantable Cardiac Defibrillator with remote integration capabilities at least 9 months prior to Screening
NYHA Functional Class I, II, or III
Frequent premature ventricular contractions (PVCs)

Exclusion criteria

Ventricular tachycardia (VT) ablation within 6 months of Screening or planned VT ablation within 6 months after Screening
High AAV9 neutralizing antibody titer
Prior myocardial infarction
Right Ventricular Heart Failure
Class IV Heart Failure
Clinically significant renal disease
Clinically significant liver disease